Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at ASTS Winter Symposium

Eledon Pharmaceuticals presented 24-month follow-up data from a Phase 1b trial of tegoprubart in kidney transplant patients. The study showed an increase in estimated glomerular filtration rate from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months, with no episodes of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or de novo donor-specific antibody formation. The data supports the safety and tolerability profile of tegoprubart.